Despite regulatory and reimbursement challenges to its erythropoietin stimulating agent (ESA) franchise, Amgen Inc. beat analyst estimates for earnings in the fourth quarter of 2007. (BioWorld Today)

MiddleBrook Pharmaceuticals Inc.'s stock skyrocketed Thursday after the FDA approved its once-daily, extended-release amoxicillin tablet, Moxatag. (BioWorld Today)